Orthobiologic Management Options for Degenerative Disc Disease

Area of Science:

• Regenerative Medicine
• Orthopedics
• Biotechnology

Background:

• Degenerative disc disease (DDD) significantly impacts quality of life and global economies.
• Current pharmacological treatments for DDD offer limited efficacy and do not address root causes.
• Orthobiologics represent a novel, regenerative therapeutic avenue for DDD.

Purpose of the Study:

• To review the pathophysiology of DDD and limitations of current treatments.
• To explore the potential of orthobiologic therapies, including platelet-rich plasma and mesenchymal stem cells.
• To assess the current clinical evidence and future research needs for orthobiologics in DDD management.

Main Methods:

• Comprehensive literature review of DDD pathophysiology and treatment modalities.
• Analysis of historical development and preclinical data for orthobiologics.
• Evaluation of clinical trial data on the efficacy of orthobiologics for DDD.

Main Results:

• Orthobiologics, such as platelet-rich plasma and mesenchymal stem cells, are emerging regenerative agents.
• Preclinical studies and early clinical trials show promising results for DDD management.
• Existing clinical evidence is insufficient for routine adoption due to study design limitations.

Conclusions:

• Orthobiologics hold significant potential to revolutionize DDD treatment.
• Further research is crucial to optimize orthobiologic therapies for consistent clinical outcomes.
• Enhanced therapeutic strategies are needed to address the underlying causes of DDD.